## FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  TILTON GLENN F						2. Issuer Name and Ticker or Trading Symbol AbbVie Inc. [ ABBV ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
TILION GLENN F					1				-					X	Direct	or		10% Ov	vner
(Last) (First) (Middle) 1 N. WAUKEGAN ROAD					3. Date of Earliest Transaction (Month/Day/Year) 09/30/2014									Office below	r (give title )		Other (s below)	specify	
(Street) NORTH CHICAC	GO IL		60064		4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)								Line)	Individual or Joint/Group Filing (Check Applicable ine)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Si	ate) (	Zip)																
		Tab	le I - Non-	-Deriva	ative	Sec	curitie	es A	cquirec	, Di	sposed	of, or B	enefic	cially	Owne	d			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Date)					Execution Date,			Code	Transaction Disposed Of (D) (Instr. 3, 4			4 and Securiti		ies Form cially (D) Following (I) (I		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amour	t (A)	Price		Transac				(111511. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																		
				Transa Code (I		of E		Expiration	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		S (I	. Price of Perivative Pecurity Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				C	Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amou or Numb of Share	er					
Stock Equivalent Units	\$0 <sup>(1)</sup>	09/30/2014			A		597		(1)		(1)	Common Stock	591	7	\$57.76	19,414 <sup>(2)</sup>		D	

## **Explanation of Responses:**

- 1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
- 2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Steven L. Scrogham, attorney-10/02/2014 in-fact for Glenn F. Tilton

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.